Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported.
More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...
Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...
The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu vaccines in the U.S. More than 18,000 adults, most of them in the U.S., were ...
NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...
Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...
PHILADELPHIA -- To help fend off another wave of Covid-19, people will need a fourth dose of vaccine, Pfizer CEO Albert Bourla said Sunday. "Many variants are coming, and Omicron was the first one ...
Advisers to Health Secretary Robert F. Kennedy Jr. are considering major revisions to the childhood vaccination schedule, including delaying or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback